Sugi Predict

Sugi Predict / Compounds / SCHEMBL2789013

SCHEMBL2789013

SCHEMBL2789013

O=C(O)c1cc(S(=O)(=O)c2ccccc2)c2ccccc2c1O

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 16/20 0.69
▸ HSD17B10 Q99714 3/20 0.69
▸ CYP2C9 P11712 2/20 0.69
▸ HPGD P15428 2/20 0.57
▸ THRB P10828 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ ALOX12 P18054 1/20 0.57
▸ ATIC P31939 1/20 0.57
▸ BCL2L1 Q07817 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1808593 0.83 MCL1 (0.73) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL2791306 0.83 MCL1 (0.49) MCL1HSD17B10CYP2C9HPGDBCL2L1
SCHEMBL590115 0.82 MCL1 (0.71) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL7234615 0.82 MCL1 (0.71) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL589651 0.82 MCL1 (1.00) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL29539793 0.82 MCL1 (0.71) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL18392411 0.78 MCL1 (1.00) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL30076571 0.78 MCL1 (1.00) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL9308849 0.77 GAA (0.46) MCL1HSD17B10CYP2C9ALDH1A1
SCHEMBL30076624 0.77 MCL1 (0.85) MCL1BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US claimed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 — — CN claimed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP claimed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO claimed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US disclosed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 — — CN disclosed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP disclosed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A MCL1 4446/4885HSD17B10 15/4885CYP2C9 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.